Although our findings suggest that FSP1 may be an effective agent for treating cisplatin induced acute kidney injury, several reports focusing on the function of extracellular FSP1 indicate that it acts as a pathological aggravating factor in cancer with the potential to induce metastasis. This evidence concerns the gene S100A4 and acute kidney injury.